Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Netanyahu Seeks Presidential Pardon Amid Ongoing Corruption Trial 
Intel Rejects TSMC’s Allegations of Trade-Secret Leaks as Legal Battle Escalates 
Mexico Probes Miss Universe President Raul Rocha Over Alleged Criminal Links 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
